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Abstract.
Background: -synuclein is a lead Parkinson’s disease (PD) biomarker. There are conflicting reports regarding accuracy of
-synuclein in different tissues and biofluids as a PD biomarker, and the within-subject anatomical distribution of-synuclein
is not well described. The Systemic Synuclein Sampling Study (S4) aims to address these gaps in knowledge. The S4 is a
multicenter, cross-sectional, observational study evaluating -synuclein in multiple tissues and biofluids in PD and healthy
controls (HC).
Objective: To describe the baseline characteristics of the S4 cohort and safety and feasibility of this study.
Methods: Participants underwent motor and non-motor clinical assessments, dopamine transporter SPECT, biofluid collection
(cerebrospinal fluid, saliva, and blood), and tissue biopsies (skin, sigmoid colon, and submandibular gland). Biopsy adequacy
was determined based on presence of adequate target tissue. Tissue sections were stained with the 5C12 monoclonal antibody
against unmodified -synuclein. All specimens were acquired and processed in a standardized manner. Adverse events were
systematically recorded.
1See appendix.
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Results: The final cohort consists of 82 participants (61 PD, 21 HC). In 68 subjects (83%), all types of specimens were
obtained but only 50 (61%) of subjects had all specimens both collected and evaluable for -synuclein. Mild adverse events
were common, especially for submandibular gland biopsy, but only 1 severe adverse event occurred.
Conclusion: Multicenter tissue and biofluid sampling for -synuclein is feasible and generally safe. S4 will inform under-
standing of the concurrent distribution of -synuclein pathology and biomarkers in biofluids and peripheral nervous system
in PD.
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INTRODUCTION
A major obstacle to development of Parkinson’s
disease (PD) therapeutics is the lack of objec-
tive disease measures. Abnormal accumulation of
-synuclein in the brain is the main pathological hall-
mark in PD and also shows a gene dosage effect [1],
making it a lead candidate PD biomarker. Multiple
reports cite-synuclein changes in different biofluids
and tissues in PD [2] and prodromal PD [3]. How-
ever, there are conflicting reports regarding sensitivity
and specificity of -synuclein in biofluids and dif-
ferent tissues as a PD biomarker. The explanation
for these conflicting reports is likely multifactorial
including small sample sizes, generally from single
centers without formal study monitoring, as well as
differences in study sample, acquisition, processing,
tissue staining, and interpretation [4]. Furthermore,
it is unknown how levels of -synuclein correlate
in different matrices (tissue and biofluids) in the
same individual. Better understanding of-synuclein
distribution in different tissues and body fluids is
essential to identifying measures of -synuclein that
serve as accurate biomarkers for diagnosis, disease
progression, target engagement and therapeutic effi-
cacy. To fully assess the utility of a biomarker for
these purposes, it is essential to account for the fea-
sibility of a biomarker’s widespread adoption and
dissemination, including ease and safety of specimen
acquisition.
The Systemic Synuclein Sampling Study (S4) is
a multicenter study that aimed to collect multiple
tissues and biofluids within the same subject, using
rigorous data/specimen collection and storage as well
as standard protocols at each step from acquisition
to interpretation. Subject recruitment and specimen
acquisition have been completed. We herein report on
the baseline characteristics of participants in the S4
study, as well as the feasibility and safety of obtain-
ing multiple tissue and biofluid specimens within the
same subjects.
METHODS
Study sample
S4 is a cross-sectional study evaluating -
synuclein pathology in multiple tissues and biofluids
in the same PD and HC subjects. Study methodology
have been described in detail elsewhere [5]. Briefly,
between October 2015 and August 2017, the study
aimed to enroll individuals with PD belonging to one
of 3 groups: 20 early PD patients within 2 years of
diagnosis, not treated with dopaminergic therapy; 20
patients with moderate disease, 2–5 years duration,
without motor fluctuations; and 20 advanced PD with
disease duration of 5 or more years and with motor
fluctuations and/or dyskinesias. Decreased dopamine
transporter (DaT) SPECT binding, based on age- and
sex- matched normative data, was required for inclu-
sion [6]. In addition, a non-PD healthy comparator
(HC) group, with normal DaT SPECT, was recruited.
Exclusion criteria in both PD and HC groups included
clinical diagnosis of dementia (Montreal Cognitive
Assessment (MoCA) score was accounted for in
determining eligibility of potential HC but not PD
participants), diabetes, bleeding diathesis, history of
submandibular gland botulinum toxin injections for
sialorrhea, active gastroenterologic-, dermatologic-,
or salivary gland disease/disorder and/or any condi-
tions that preclude the safe performance of the lumbar
puncture, flexible sigmoidoscopy, skin biopsy, or sub-
mandibular gland biopsy. While the goal was to
obtain all biofluids and all tissues on all subjects,
a minimum of 2 biofluid types and 2 tissue proce-
dures were required to consider subjects as having
completed study participation; target recruitment was
80 subjects with at least 2 biofluids and 2 tissues
collected.
The study was approved by institutional review
boards at each S4 site, and written informed consent
was obtained.
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Tissue and bioﬂuid acquisition procedures
Biopsies of the skin, sigmoid colon, and sub-
mandibular gland were obtained as described [5] and
are detailed in the S4 biologics manual [7]. Briefly,
skin biopsies were performed using a 3 mm punch
biopsy tool under local anesthesia. This procedure
was performed by the site PI (Neurologist) at 3
sites, by a PA at 2 sites, and a surgeon at 1 site.
Two biopsies were obtained from the paravertebral
posterior cervical region and 2 from the ipsilateral
mid-thigh. Colon biopsy was performed by gastroen-
terologists through flexible sigmoidoscopy. Up to 8
biopsies were obtained. Submandibular gland nee-
dle biopsy was performed by otolaryngologists under
local anesthesia using a 16-gauge core biopsy instru-
ment. Initially, up to 5 biopsies were obtained, but
after the occurrence of a serious adverse event (see
below) 12 months into the study, the protocol was
changed to allow up to 4 biopsies. Ultrasound guid-
ance of submandibular gland biopsy was optional and
was used at only 1 of the 6 study sites. Proceduralist
training was performed by a specialist experienced in
each biopsy type (experienced generally, and specif-
ically in individuals with PD). Training occurred via
live webinar.
Biofluids were obtained and processed as pre-
viously described [5] and are detailed in the S4
biologics manual [7]. Briefly, lumbar puncture (LP)
was performed with a goal volume of collection of
20 mL of cerebrospinal fluid (CSF). Use of a 24 gauge
(g) atraumatic (Sprotte) needle was recommended,
but 20 g or 22 g needles were allowed in instances
where fluoroscopy-guided LP was performed. Pas-
sive saliva collection was performed, with a goal of
5 mL collected. Blood was collected by venous punc-
ture and processed into plasma, serum, and whole
blood.
The goal was for acquisition of all specimens to
occur within 120 days of the screening visit.
Specimen processing and staining/assaying for
α-synuclein
The flow of specimens and determination of spec-
imen adequacy at each step is shown schematically
in Fig. 1.
Tissue processing and packaging steps have been
previously described [5] and are detailed in the S4
biologics manual [7]. Briefly, skin, submandibular
gland, and colon tissue biopsy specimens were placed
between sponges within a standard plastic embedding
cassette and then immersed in 10% formalin (2–3
biopsy fragments were placed in each cassette).
These were then shipped to the biorepository where
all contents of a single cassette were embedded
into a paraffin block. Each formalin-fixed paraffin-
embedded (FFPE) block was cut completely through
into 4m sections mounted on individual slides. Four
equidistant sections from each cassette were stained
with hematoxylin and eosin (H&E). Images of the
H&E stained slides were sent to the neuropathology
core for determination of presence of adequate target
tissue (see below). Three slides from each cassette
with adequate target tissue were selected and shipped
to a contract research organization (CRO) Targos
Molecular Pathology GmbH, located in Kassel,
Germany. There, paraffin-embedded tissue sections
were stained on an automated Ventana BenchMark®
platform with the 5C12 monoclonal antibody as
described [8]. Positive and negative control slides
were included with each staining run. These con-
sisted of slides of post-mortem neuropathologically
examined tissue (2 each of cerebral cortex, skin (pos-
terior scalp), and colon) obtained from PD and HC
subjects known to be clearly positive or negative
for-synuclein pathology respectively. Once positive
and negative controls were reviewed, digital images
of the slides were then taken at 40x resolution, placed
on flash drives, and shipped to the neuropathology
core (core PI author TGB, at Banner Sun Health
Research Institute) as well as to 3 independent and
blinded histopathology judges (medically-certified
neuropathologists). The neuropathology core and
histopathology judges individually reviewed and
rated the slides semi-quantitatively for presence of
-synuclein.
Biofluids were processed as detailed in the S4
biologics manual [7]. Briefly, CSF was centrifuged
at 2000 xg for 10 minutes at room temperature
(18◦C to 25◦C). The supernatant was aliquoted into
pre-cooled polypropylene CSF collection aliquot
tubes, placed on dry ice within 60 minutes of
collection, and then stored at –80◦C until shipped
on dry ice to the biorepository. As for saliva, 10X
protease inhibitor cocktail (PIC) was added to the
saliva sample and, within 30 minutes of collection,
centrifuged at 4◦C at 2000 xg for 15 minutes. Saliva
was then aliquoted into pre-cooled microcentrifuge
tubes and stored at –80◦C until shipped on dry ice
to the biorepository. Blood was collected by venous
puncture into EDTA tubes for whole blood, DNA,
plasma, and buffy coat. Blood was also collected
in a serum tube for serum aliquots and PAXGene
520 L.M. Chahine et al. / Multicenter Tissue and Bioﬂuid Study in PD
Fig. 1. Steps in tissue processing and assessment of adequacy in S4. Steps for assessments of safety and feasibility are highlighted in grey.
AE, adverse event; CRO, contract research organization; FFPE, formalin-fixed paraffin-embedded; H&E, hematoxylin and eosin.
tubes for RNA. Specimens were processed as
detailed in the S4 biologics manual [7] and stored
at –80◦C until shipped on dry ice to the biorepos-
itory. DNA and RNA were extracted as described
(http://www.ppmi-info.org/study-design/research-
documents-and-sops/), with one modification: in S4,
one RNA tube was utilized for miRNA extraction and
another for total RNA extraction, with 2 remaining
PAXgene tubes stored for future use.
Total -synuclein was measured on CSF, saliva,
whole blood, plasma, and serum using enzyme-
linked immunosorbent assay (ELISA) BioLegend
-Synuclein Immunoassay (BioLegend, San Diego,
CA, USA; Cat. No. 844101) as described [9]. Con-
centrations of hemoglobin in plasma and serum
were measured using the QuantiChrom test (BioAs-
say Systems, Cat. No. DIHB-250)). Concentration
of hemoglobin in CSF was measured using the
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Human Hemoglobin ELISA Quantitaton Set (Bethyl
Laboratories, Cat. No. E88-134). Concentrations of
hemoglobin in whole blood and saliva were measured
using the enzyme-linked immunosorbent assay from
Bethyl Laboratories (Cat. No. E88-134).
Metrics of feasibility
Feasibility of the tissue acquisition procedure was
captured at various stages of the study, as depicted
in the schematic shown in Fig. 1. Feasibility was
quantified using several metrics:
1) Whether the procedure was attempted and
whether any tissue was obtained, as documented
by the study coordinator on the case report form.
2) Whether the tissue obtained contained “adequate”
target tissue, as determined following review of
the H&E stained slides at the neuropathology
core. Adequate biopsy was defined by at least
one fragment of a given tissue type containing a
minimal amount (2 mm2) of target tissue. Target
tissue was defined as glandular tissue (epithe-
lial secretory acini and intervening stroma) for
submandibular gland, submucosa for colon, and
dermis for skin. Multiple cassettes (each contain-
ing one or more fragments of biopsy) could be
obtained per subject per tissue biopsy. A binary
determination of adequate biopsy, defined as a
minimum of one cassette with adequate target tis-
sue for a given tissue type for a given subject, was
assessed. An inadequate specimen was defined by
absence or insufficient amount of target tissue in
a given cassette.
3) Feasibility of staining was assessed by the num-
ber of slides that were determined to have been
adequately stained divided by the total num-
ber of stained slides. This determination was
jointly made for each slide by the CRO and the
neuropathology core.
Biofluid collection feasibility was assessed with
number of specimens and volume collected. In
addition, CSF samples with hemoglobin level
of > 200 ng/mL were also considered as a metric of
feasibility, as this degree of hemoglobin contami-
nation of CSF may be significant enough to affect
measurements of CSF total -synuclein [10].
Metrics of safety
Adverse event data were collected at the vis-
its (during in-person subject assessment by the site
coordinator and/or PI) and during follow-up via
phone calls performed at 7 days (±2 days) of each
procedure. Adverse events (AEs) were graded 1–5
as defined in the Common Terminology Criteria for
Adverse Events (CTCAE) [11], and summarized as
follows: mild, grade 1: aware of event but easily toler-
ated; moderate, grade 2: discomfort, enough to cause
interference with usual activity; severe, grade 3: inca-
pacitating: subject unable to work or perform usual
activities; life-threatening, grade 4; and death, grade
5. A serious adverse event (SAE) was defined as a
grade 4 or 5 AE. Only AE’s considered to be at least
possibly related to a study procedure are considered
in this analysis.
Statistical analysis
Analyses were performed using SAS 9.4 (SAS
Institute Inc., Cary, NC). Descriptive statistics were
used to summarize basic demographics and metrics
of safety and feasibility. For continuous variables,
differences between the PD and HC groups were
examined using two-sample t-tests or Wilcoxon
rank sum tests, where appropriate. For ordinal vari-
ables the Cochran-Armitage test for trend was used
while chi-squared tests or Fisher’s exact tests were
implemented for categorical variables.
A range of generalized linear models and general-
ized linear mixed models were used to explore pre-
dictors of the various response variables. A logistic
regression model was used to explore the predictors of
inadequate tissue acquisition while linear regression
models were used to look at associations of saliva
volume. Adverse event rate was calculated as the
number of AEs per number of procedures assessed.
The difference in adverse event rates between
groups was evaluated using a negative binomial
model (due to evidence of overdispersion).
A mixed effects logistic regression model was used
to explore the relationship between study site and the
odds of obtaining an inadequate sample. The model
included a random intercept that clustered on indi-
vidual while also adjusting for tissue type.
RESULTS
Of 100 individuals who participated in S4
screening activities, 18 were deemed ineligible to
participate. Reasons for exclusion were: MoCA
score (n = 5), negative DaT SPECT scan (n = 6),
antiplatelet/anticoagulant use (n = 1), comorbid dis-
ease (cancer, diabetes; n = 2), did not qualify based
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on PD disease duration and/or manifestations (n = 2),
and not suitable for study participation per investiga-
tor discretion (not otherwise specified; n = 2).
Eighty-two subjects were enrolled, 61 with PD
and 21 HCs. Characteristics of enrolled subjects are
shown in Table 1. Of those that enrolled, 80 com-
pleted collection of at least 2 biofluids and 2 tissues.
Mean time for completion of study participation was
41 days (range 2–127).
Feasibility data are shown in Table 2. Skin biopsy
was collected on all but 2 subjects, both of whom
declined to undergo the procedure. Colon biopsy was
attempted on all but 1 subject who declined to have
the study procedure. Submandibular gland biopsy
was not attempted in 5 subjects who also declined
to have this procedure; in 1 instance submandibu-
lar gland biopsy was attempted but tissue could not
be obtained. Adequacy of obtained target tissue was
high for skin and colon but lower for submandibular
gland (among specimens obtained, percent with at
least some adequate tissue: 97.6% for skin, 96.3%
for colon, 68.3% for submandibular gland). The
odds of an inadequate submandibular gland speci-
men increased by 11% for each 1-year increase in
age (OR = 1.11; 95% CI 1.03–1.19; p < 0.006). There
were no significant associations between biopsy ade-
quacy and sex, group (PD vs. HC), or PD disease
duration or severity (data not shown). The number of
subjects with at least 1 adequate submandibular gland
specimen obtained was highest at one study site that
used ultrasound-guidance [11 (85%) of 13 enrolled
subjects at that site] and one site that did not [9 (82%)
of 11 subjects enrolled at that site]. At other sites, all
of which did not use ultrasound guidance, the per-
centage of subjects with at least 1 adequate specimen
ranged from 44–74%. The proportion of submandibu-
lar specimens obtained that were inadequate was not
lower at the site that used ultrasound (13%) vs. sites
that did not (10–67%) (p = 0.55). Forty-one (67%) of
the PD group and 14 (67%) of the HC group had
adequate specimens of each of the 3 tissue types.
In regards to biofluid collection, CSF collection
was attempted on all HC and 60 (98%) PD sub-
jects and successfully obtained in 75 (93%) of those
attempted. Ten CSF samples had a hemoglobin level
of > 200 ng/mL. The proportion of specimens with
Hb > 200 was greater for the 10 CSF specimens
obtained with LP needle gauge of 20 or 22 (3/10
(30%)), though this difference was not statistically
significant (p = 0.12).
Saliva collection was attempted on all subjects
but collected saliva volume was lower than goal for
many participants. This was anecdotally reported by
coordinators to be due to dry mouth/inability of the
participant to produce saliva. The volume of saliva
collected was not associated with age, sex, disease
duration, current or former tobacco use, hours since
last food/liquid intake, and hours since last use of oral
hygiene products (data not shown). Blood samples
were obtained on all but 1 subject.
All possible tissues and biofluids were collected on
48 (79%) of the PD group and 20 (95%) of the HC
group (p = 0.10 for difference between groups). How-
ever, a lesser fraction, 36 (59%) PD and 14 (67%) HC
subjects, had evaluable specimens of all biofluids and
tissue. This difference between the number with all
specimens collected vs. all specimens adequate (eg
evaluable for -synuclein) is mainly accounted for
by the proportion of inadequate specimens obtained
with submandibular gland biopsy. If CSF hemoglobin
(which could influence measurement of CSF total -
synuclein) is accounted for in the evaluability of CSF,
30 (49%) PD and 13 (62%) HC subjects had all spec-
imens collected and evaluable (with evaluable here
defined as CSF hemoglobin <200 ng/dL, and at least
1 adequate cassette for each tissue type).
Safety data are shown in Table 3. In regards to
adverse events (AEs), among those who had colon
biopsy, only 1 AE was reported, documented as
diarrhea following the procedure. Eight AEs were
reported in those who had skin biopsy, including 3
with contusions, 2 with pain, and two with signs
of inflammation. Seventy AEs from submandibular
gland were reported. The vast majority of AEs from
SMG biopsy were mild/grade I (76%); 25% were
moderate. The most commonly reported AEs with
SMG included pain in 22 instances, swelling in 20,
hematoma and/or contusion in 21. In regards to AEs
with biofluid collection, mild AEs were reported for
CSF collection in 12% of those who underwent the
procedure (Table 3). There were no AEs reported for
saliva collection or phlebotomy. There were no sig-
nificant differences in AE rate in the PD group vs. the
HC group for SMG biopsy (rate of AE for other tissue
type biopsies was too low to compare for significant
differences between groups).
There was 1 serious adverse event in the entire
study, related to SMG biopsy complicated by sub-
lingual hematoma which manifested with pain,
dysarthria, dysphagia and dyspnea. This resolved
without intervention.
A total of 106,624 slides were generated from S4
specimens: 35,316 skin, 44,383 colon, and 26,925
submandibular gland. A total of 1,782 were sent to
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Table 1
S4 Cohort demographic and clinical characteristics SD = standard deviation
Variable PD N = 61 HC N = 21
Mean Age in years (SD; range) 62.9 (8.6; 43.6–85.5) 61.0 (6.3; 51.3–71.3)
Gender, N (%)
Male 41 (67) 9 (43)
Female 20 (33) 12 (57)
Ethnicity, N (%)
Hispanic/Latino 1 (2) 0 (0)
Not Hispanic/Latino 60 (98) 21 (100)
Race, N (%)
White 59 (97) 20 (95)
Not White 2 (3) 1 (5)
Mean Years of Education (SD; range) 17.6 (3.09; 10.0–25.0) 17.19 (3.17; 12.0–24.0)
Mean Symptom Duration (Months) (SD; range) 74.8 (57.2; 2.8–251.3) N/A
Mean Disease Duration in months (SD; range) 56.0 (54.9; 1.1–245.3) N/A
Mean MDS-UPDRS Total Off Score (SD; range) 44.2 (19.0; 8.0–90.0) 4.3 (3.7; 0.0–14.0)
Missing* 5 0
Mean MDS-UPDRS III Off Score (SD; range) 26.5 (11.8; 7.0–56.0) 1.1 (2.31; 0.0–10.0)
Missing 5 0
Hoehn and Yahr Stage, N (%)**
0 1 (1.6) N/A
1 12 (19.7)
2 41 (67.2)
3 7 (11.5)
*off testing was not possible on 5 participants with advanced PD who could not abstain from taking their medications
for a few hours without significant discomfort. **These represent Hohen and Yahr in the OFF state except in the
5 subjects who were not able to complete OFF testing.
Table 2
Feasibility of tissue and biofluid collection. SD = Standard deviation
Specimen type Metric PD (N = 61) HC (N = 21) Total (n = 82)
Colon biopsy Procedure completed, N (%) 60 (98.4) 21 (100) 81 (98.8)
At least some biopsies
adequate, N (%)
58 (95.1) 21 (100) 79 (96.3)
Skin biopsy Procedure completed, N (%) 59 (96.7) 21 (100) 80 (97.6)
At least some biopsies
adequate, N (%)
59 (96.7) 21 (100) 80 (97.6)
Submandibular gland biopsy Procedure completed, N (%) 56 (91.8) 20 (95.2) 76 (92.7)
At least some biopsies
adequate, N (%)
42 (68.9) 14 (66.7) 56 (68.3)
Lumbar Puncture Procedure completed, N (%) 54 (88.5) 21 (100) 75 (91.5)
CSF sample with hemoglobin
value <200 ng/mL
46 (75.4) 19 (90.5) 65 (79.3)
Mean cerebrospinal fluid
volume obtained (SD; range)
15.56 (2.3; 7.5–21.0) 15.90 (1.5; 15.0–19.5) 15.66 (2.1; 7.5–21.0)
Saliva Collection Procedure completed, N (%) 57 (93.4) 21 (100) 78 (95.1)
Mean Saliva fluid volume
obtained mL (SD; range)
4.08 (2.2; 0.40–10.00) 4.92 (2.4; 0.80–10.00) 4.30 (2.2; 0.40–10.00)
Phlebotomy Procedure completed, N (%) 60 (98.4) 21 (100) 81 (98.8)
the CRO and stained. Ninety-six (5.4%) slides were
determined to not meet the minimum staining quality
required.
DISCUSSION
Our results demonstrate that multisite tissue and
biofluid sampling for -synuclein in a multicenter
study is feasible and generally safe. It is notable
that it is possible to recruit a cohort to undergo rel-
atively intensive and demanding study procedures
with a high procedure completeness rate over just
a 22-month study period. The yield of skin and
colon biopsies was very high, and was fair for sub-
mandibular gland. Additionally, despite the logistical
complexity of multiple study sites and cores, nation-
ally and internationally, the number of successfully
524 L.M. Chahine et al. / Multicenter Tissue and Bioﬂuid Study in PD
Table 3
Safety of Tissue and Biofluid Collection
Specimen type Metric PD HC Total
Colon biopsy Procedure completed, N 60 21 81
Number of subjects with AE from colon biopsy, N (% of those completed) 0 (0) 1 (4.8)* 1 (1.2)
Total number of AE from colon biopsy, N 0 1 1
Mild (Grade 1) AE from colon biopsy, N 0 1 1
Moderate (Grade 2) AE from colon biopsy, N 0 0 0
Severe (Grade 3) AE from colon biopsy, N 0 0 0
Life-threating (Grade 4) AE from colon biopsy, N (serious AE) 0 0 0
AE rate 0 0.05 0.01
Skin biopsy Procedure completed, N 59 21 80
Number of subjects with AE from skin biopsy, N (% of those completed) 2 (3.4) 5 (23.8) 7 (8.8)
Total number of AE from skin biopsy, N 2 6 8
Mild (Grade 1) AE from skin biopsy, N 2 6 8
Moderate (Grade 2) AE from skin biopsy, N 0 0 0
Severe (Grade 3) AE from skin biopsy, N 0 0 0
Life-threating (Grade 4) AE from skin biopsy, N (serious AE) 0 0 0
AE rate 0.03 0.29 0.10
Submandibular gland biopsy Procedure completed, N 56 20 76
Number of subjects with AE from SMG biopsy, N (% of those completed) 30 (53.6) 13 (65.0) 43 (56.6)
Total number of AE from SMG biopsy, N 52 18 70
Mild (Grade 1) AE from SMG biopsy, N 41 12 53
Moderate (Grade 2) AE from SMG biopsy, N 11 6 17
Severe (Grade 3) AE from SMG biopsy, N 0 0 0
Life-threating (Grade 4) AE from SMG biopsy, N (serious AE) 1 0 1
AE rate 0.93 0.90 0.92
Lumbar Puncture Procedure completed, N 54 21 75
Number of subjects with AE from CSF acquisition, N (% of those completed) 8 (14.8) 1 (4.8) 9 (12.0)
Total number of AE from CSF acquisition, N 10 1 11
Mild (Grade 1) AE from CSF acquisition, N 10 1 11
Moderate (Grade 2) AE from CSF acquisition, N 0 0 0
Severe (Grade III) AE from CSF acquisition, N 0 0 0
Life-threating (Grade 4) AE from CSF acquisition, N (serious AE) 0 0 0
AE rate 0.19 0.05 0.15
Saliva Collection Procedure completed, N 57 21 78
Number of subjects with AE from saliva acquisition, N (% of those completed) 0 0 0
Phlebotomy Procedure completed, N 60 21 81
Number of subjects with AE from phlebotomy, N 0 0 0
*AEs from colon biopsy were assessed for only 80 subjects; there was one HC subject who completed the colon biopsy but documentation
of post-procedural AEs assessment was not completed for this subject. AE, adverse event.
stained slides was high. Importantly, there was only
one serious adverse event across all procedures.
Generally, procedure completeness, success, and
adverse event rate is operator-dependent to a large
extent. For each of the procedures conducted, peer
training occurred via webinar by a specialist experi-
enced in the procedure of interest. At each study site,
there were varying degrees of prior experience with
the procedures performed.
A Neurologist or Neurology physician assistant
(PA) performed the skin biopsies at several sites. Most
Neurologists and Neurology PAs do not have train-
ing in skin biopsy, so it is of note that the yield of
skin biopsy was high, supporting the feasibility of
Neurologists/Neurology PAs to learn this procedure
with targeted training and also perform this procedure
with high yield. Regarding the SMG biopsy pro-
cedure, all otolaryngologists who performed it for
S4 had reported previously performing SMG biopsy
for clinical purposes, but prior volume and situa-
tional experience with it was not captured in study
data. Despite the variability that could be introduced
by having otolaryngologists at different sites and
with different levels of experience performing SMG
biopsies, the yield of adequate SMG in this study
of 77% (of attempted) is similar to or greater than
what has been reported in other single-site studies.
In a study involving SMG biopsy, Adler et al. [2]
defined insufficient biopsy as a maximal aggregated
area of SMG tissue of <2 mm2, as was done for
S4. Based on that definition, 8 of their 35 subjects
(23%) had insufficient specimens. Given anatomic
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considerations, this lower yield in SMG biopsy com-
pared to colon and skin biopsy is not surprising. The
increased risk of inadequate specimen with higher
age is also not surprising, as SMG volume decreases
with age [12]. Data on whether ultrasound guid-
ance for SMG biopsy significantly improves yield
are limited. Some literature suggests increased yield
of normal gland and gland tumors with ultrasound
guidance [13, 14]. However, one prior study of SMG
biopsy for PD/RBD utilized ultrasound but achieved
adequate tissue in less than 50% of subjects [3]. In
addition, use of ultrasound was seen as a significant
logistical limitation at many S4 sites (both in terms
of availability of ultrasound machines and techni-
cians to the otolaryngologists as well as the training
required to use ultrasound by the otolaryngologists)
and was therefore made optional. In S4, the one site
that used ultrasound-guidance for the SMG biopsy
had the highest percentage acquisition of adequate
tissue but this did not significantly differ from another
site that did not use ultrasound guidance.
Collection of all specimens occurred in 83% of the
cohort as a whole; this was higher in the HC group
as compared to the PD group though the difference
between the groups did not reach statistical signifi-
cance. It is possible that completion of some of the
procedures was more challenging in the PD group due
to their disease manifestations (eg fatigue, mobility
issues). Data on specific reasons for lack of comple-
tion of specific study activities were not collected in
this study and warrant systematic tracking in future
studies. As for the adequacy of specimens collected,
for the cohort as a whole, all specimens were collected
and adequate in 61%. The difference between propor-
tion of subjects with all specimens collected vs. all
specimens collected and adequate is driven mainly
by the rate of inadequate submandibular gland spec-
imens: in 20 subjects, submandibular gland biopsy
was completed but yielded no target tissue. In addi-
tion, 10 CSF specimens had Hb > 200 ng/mL which
may affect measurement of total -synuclein in those
samples as well. Higher age was associated with
increased odds of an inadequate SMG specimen, and
the majority of cases with CSF Hb > 200 ng/mL were
in the PD group. Otherwise, we did not find predictors
of inadequate specimens. However, these analyses are
limited by small sample sizes. Thus, all multivari-
ate analyses presented were underpowered to detect
differences and should be interpreted with great
caution.
While the rate of adverse events related to SMG
biopsy was high, the vast majority of AEs were mild.
A similarly high mild AE rate for SMG biopsy in PD
has occurred in other studies: 77% [2]. Reassuringly,
the number of serious adverse events in S4 was lim-
ited to a single instance and has not been reported
in other studies of SMG biopsy in PD or RBD [2, 3,
15]. Increasing the number of passes into the gland
with the core needle biopsy tool likely increases both
yield and AE rate, and these considerations will both
need to be weighed in future studies of SMG biopsy
in PD. We did not identify any significant predictors
of adverse event occurrence, but again this should
be interpreted with caution given the relatively small
sample size.
The results presented here give confidence that if,
with future analyses of S4 results, -synuclein in
any of the obtained tissues and biofluids emerges
as a promising PD biomarker, further studies to val-
idate such a biomarker can be feasibly and safely
conducted. When taking the feasibility and safety
results together and contrasting them across all spec-
imens obtained, SMG biopsy is notable for having
the lowest yield and highest adverse event rate.
Thus, if S4 demonstrates potential utility of SMG
-synuclein as a PD biomarker, future work will
be needed to improve yield of SMG biopsy, and
improve on the adverse event rate. On the other hand,
if measures of -synuclein in other peripheral sites or
biofluids demonstrate comparable accuracy to SMG
-synuclein as PD biomarkers, the safety profile of
SMG biopsy may render SMG -synuclein of lower
priority for future development as PD biomarker, in
favor of safer alternatives.
We have demonstrated that multicenter tissue and
biofluid sampling for -synuclein in PD is feasible
and safe. These data will be useful in estimating
biopsy yield in sample size calculations for future PD
clinical trials and observational studies incorporating
tissue sampling. Future analyses of these S4 spec-
imens will address the question of intra-individual
distribution of -synuclein in PD.
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